Schuerer Douglas J E, Zack Jeanne E, Thomas James, Borecki Ingrid B, Sona Carrie S, Schallom Marilyn E, Venker Melissa, Nemeth Jennifer L, Ward Myrna R, Verjan Linda, Warren David K, Fraser Victoria J, Mazuski John E, Boyle Walter A, Buchman Timothy G, Coopersmith Craig M
Department of Surgery, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
Surg Infect (Larchmt). 2007 Aug;8(4):445-54. doi: 10.1089/sur.2006.073.
Current guidelines recommend using antiseptic- or antibiotic-impregnated central venous catheters (CVCs) if, following a comprehensive strategy to prevent catheter-related blood stream infection (CR-BSI), infection rates remain above institutional goals based on benchmark values. The purpose of this study was to determine if chlorhexidine/silver sulfadiazine-impregnated CVCs could decrease the CR-BSI rate in an intensive care unit (ICU) with a low baseline infection rate.
Pre-intervention and post-intervention observational study in a 24-bed surgical/trauma/burn ICU from October, 2002 to August, 2005. All patients requiring CVC placement after March, 2004 had a chlorhexidine/silver sulfadiazine-impregnated catheter inserted (post-intervention period).
Twenty-three CR-BSIs occurred in 6,960 catheter days (3.3 per 1,000 catheter days)during the 17-month control period. After introduction of chlorhexidine/silver sulfadiazine-impregnated catheters, 16 CR-BSIs occurred in 7,732 catheter days (2.1 per 1,000 catheter days; p = 0.16). The average length of time required for an infection to become established after catheterization was similar in the two groups (8.4 vs. 8.6 days; p = 0.85). Chlorhexidine/silver sulfadiazine-impregnated catheters did not result in a statistically significant change in the microbiological profile of CR-BSIs, nor did they increase the incidence of resistant organisms.
Although chlorhexidine/silver sulfadiazine-impregnated catheters are useful in specific patient populations, they did not result in a statistically significant decrease in the CR-BSI rate in this study, beyond what was achieved with education alone.
当前指南建议,如果在采取全面预防导管相关血流感染(CR-BSI)策略后,感染率仍高于基于基准值的机构目标,则使用含抗菌剂或抗生素的中心静脉导管(CVC)。本研究的目的是确定在基线感染率较低的重症监护病房(ICU)中,氯己定/磺胺嘧啶银浸渍的CVC是否能降低CR-BSI发生率。
2002年10月至2005年8月,在一家拥有24张床位的外科/创伤/烧伤ICU进行干预前和干预后的观察性研究。2004年3月后所有需要放置CVC的患者均插入氯己定/磺胺嘧啶银浸渍导管(干预后期)。
在17个月的对照期内,6960个导管日中发生了23例CR-BSI(每1000个导管日3.3例)。引入氯己定/磺胺嘧啶银浸渍导管后,7732个导管日中发生了16例CR-BSI(每1000个导管日2.1例;p = 0.16)。两组导管插入后感染确立所需的平均时间相似(8.4天对8.6天;p = 0.85)。氯己定/磺胺嘧啶银浸渍导管未导致CR-BSI的微生物谱发生统计学显著变化,也未增加耐药菌的发生率。
尽管氯己定/磺胺嘧啶银浸渍导管在特定患者群体中有用,但在本研究中,它们并未使CR-BSI发生率出现统计学显著下降,仅靠教育所取得的效果之外并无额外显著效果。